USFDA Fast-Track Drug Review Programme in Limbo Under Trump

RecentNews.uk

USFDA fast-track drug review programme has stalled under the Trump administration.

Regulatory limbo creates uncertainty for pharmaceutical development timelines.

Global drug companies coordinate closely with US approval pathways.

Industry stakeholders await official guidance from health authorities.

Should international drug regulators align their approval timelines with the USFDA?

Tap below to vote and see what others think.